271 related articles for article (PubMed ID: 12700711)
1. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys.
Andersen MB; Fink-Jensen A; Peacock L; Gerlach J; Bymaster F; Lundbaek JA; Werge T
Neuropsychopharmacology; 2003 Jun; 28(6):1168-75. PubMed ID: 12700711
[TBL] [Abstract][Full Text] [Related]
2. The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys.
Andersen MB; Fuxe K; Werge T; Gerlach J
Behav Pharmacol; 2002 Dec; 13(8):639-44. PubMed ID: 12478214
[TBL] [Abstract][Full Text] [Related]
3. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice.
Woolley ML; Carter HJ; Gartlon JE; Watson JM; Dawson LA
Eur J Pharmacol; 2009 Jan; 603(1-3):147-9. PubMed ID: 19111716
[TBL] [Abstract][Full Text] [Related]
4. The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat.
Stanhope KJ; Mirza NR; Bickerdike MJ; Bright JL; Harrington NR; Hesselink MB; Kennett GA; Lightowler S; Sheardown MJ; Syed R; Upton RL; Wadsworth G; Weiss SM; Wyatt A
J Pharmacol Exp Ther; 2001 Nov; 299(2):782-92. PubMed ID: 11602695
[TBL] [Abstract][Full Text] [Related]
5. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
Mirza NR; Peters D; Sparks RG
CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557
[TBL] [Abstract][Full Text] [Related]
6. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
Barak S; Weiner I
Int J Neuropsychopharmacol; 2011 Oct; 14(9):1233-46. PubMed ID: 21211109
[TBL] [Abstract][Full Text] [Related]
7. Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1/M4 preferring muscarinic receptor agonist xanomeline.
Dencker D; Wörtwein G; Weikop P; Jeon J; Thomsen M; Sager TN; Mørk A; Woldbye DP; Wess J; Fink-Jensen A
J Neurosci; 2011 Apr; 31(16):5905-8. PubMed ID: 21508215
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic-like effect of the muscarinic acetylcholine receptor agonist BuTAC in non-human primates.
Andersen MB; Croy CH; Dencker D; Werge T; Bymaster FP; Felder CC; Fink-Jensen A
PLoS One; 2015; 10(4):e0122722. PubMed ID: 25880220
[TBL] [Abstract][Full Text] [Related]
9. The substituted (S)-3-phenylpiperidine (-)-OSU6162 reduces apomorphine- and amphetamine-induced behaviour in Cebus apella monkeys.
Brandt-Christensen M; Andersen MB; Fink-Jensen A; Werge T; Gerlach J
J Neural Transm (Vienna); 2006 Jan; 113(1):11-9. PubMed ID: 15795789
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M
Mandai T; Kasahara M; Kurimoto E; Tanaka M; Suzuki M; Nakatani A; Kimura H
Neuroscience; 2019 Aug; 414():60-76. PubMed ID: 31299348
[TBL] [Abstract][Full Text] [Related]
11. Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.
Shannon HE; Rasmussen K; Bymaster FP; Hart JC; Peters SC; Swedberg MD; Jeppesen L; Sheardown MJ; Sauerberg P; Fink-Jensen A
Schizophr Res; 2000 May; 42(3):249-59. PubMed ID: 10785583
[TBL] [Abstract][Full Text] [Related]
12. Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline.
Stengel PW; Cohen ML
J Pharmacol Exp Ther; 2001 Mar; 296(3):818-24. PubMed ID: 11181912
[TBL] [Abstract][Full Text] [Related]
13. M
Russell JK; Ingram SM; Teal LB; Lindsley CW; Jones CK
ACS Chem Neurosci; 2023 Feb; 14(3):435-457. PubMed ID: 36655909
[TBL] [Abstract][Full Text] [Related]
14. Chronic dopamine D1, dopamine D2 and combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys: antiamphetamine effects and extrapyramidal side effects.
Peacock L; Hansen L; Mørkeberg F; Gerlach J
Neuropsychopharmacology; 1999 Jan; 20(1):35-43. PubMed ID: 9885783
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological analysis of the novel mode of interaction between xanomeline and the M1 muscarinic acetylcholine receptor.
Christopoulos A; Parsons AM; El-Fakahany EE
J Pharmacol Exp Ther; 1999 Jun; 289(3):1220-8. PubMed ID: 10336509
[TBL] [Abstract][Full Text] [Related]
16. The acetylcholinesterase inhibitor galantamine inhibits d-amphetamine-induced psychotic-like behavior in Cebus monkeys.
Andersen MB; Werge T; Fink-Jensen A
J Pharmacol Exp Ther; 2007 Jun; 321(3):1179-82. PubMed ID: 17374745
[TBL] [Abstract][Full Text] [Related]
17. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors.
Watson J; Brough S; Coldwell MC; Gager T; Ho M; Hunter AJ; Jerman J; Middlemiss DN; Riley GJ; Brown AM
Br J Pharmacol; 1998 Dec; 125(7):1413-20. PubMed ID: 9884068
[TBL] [Abstract][Full Text] [Related]
18. Classics in Chemical Neuroscience: Xanomeline.
Bender AM; Jones CK; Lindsley CW
ACS Chem Neurosci; 2017 Mar; 8(3):435-443. PubMed ID: 28141924
[TBL] [Abstract][Full Text] [Related]
19. Effects of central muscarinic-1 receptor stimulation on blood pressure regulation.
Medina A; Bodick N; Goldberger AL; Mac Mahon M; Lipsitz LA
Hypertension; 1997 Mar; 29(3):828-34. PubMed ID: 9052903
[TBL] [Abstract][Full Text] [Related]
20. Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232).
Bymaster FP; Wong DT; Mitch CH; Ward JS; Calligaro DO; Schoepp DD; Shannon HE; Sheardown MJ; Olesen PH; Suzdak PD; Swedberg MD; Sauerberg P
J Pharmacol Exp Ther; 1994 Apr; 269(1):282-9. PubMed ID: 7909558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
